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Transient neonatal diabetes mellitus caused by a de 
novo ABCC8 gene mutation 
Transient neonatal diabetes mellitus (TNDM) is a rare form of diabetes 
mellitus that presents within the first 6 months of life with remission 
in infancy or early childhood. TNDM is mainly caused by anomalies 
in the imprinted region on chromosome 6q24; however, recently, 
mutations in the ABCC8 gene, which encodes sulfonylurea receptor 1 
(SUR1), have also been implicated in TNDM. Herein, we present the 
case of a male child with TNDM whose mutational analysis revealed 
a heterozygous c.3547C>T substitution in the ABCC8 gene, leading 
to an Arg1183Trp mutation in the SUR1 protein. The parents were 
clinically unaffected and did not show a mutation in the ABCC8 gene. 
This is the first case of a de novo ABCC8 gene mutation in a Korean 
patient with TNDM. The patient was initially treated with insulin and 
successfully switched to sulfonylurea therapy at 14 months of age. 
Remission of diabetes had occurred at the age of 16 months. Currently, 
the patient is 21 months old and is euglycemic without any insulin 
or oral hypoglycemic agents. His growth and physical development 
are normal, and there are no delays in achieving neurological and 
developmental milestones. 
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(SUR1) of the adenosine triphosphate (ATP)-sensitive potassium 
(KATP) channel that is expressed at the surface of pancreatic beta 
cells. Closure of the KATP channel causes calcium ion influx and 
exocytosis of insulin from pancreatic beta cells
3). Mutations in the 
ABCC8 gene cause diabetes by reducing the channel’s ability to close 
in response to increased ATP and reduced adenosine diphosphate 
concentrations
1). Here, we describe the first case of a de novo ABCC8 
gene mutation in a Korean patient with TNDM. This mutation 
predicts a codon change from arginine to tryptophan at residue 1183 
(Arg1183Trp), which is located in a functionally critical region of the 
KATP channel in pancreatic beta cells.
Introduction
Transient neonatal diabetes mellitus (TNDM) is a rare form 
of diabetes diagnosed in the first 6 months of life. TNDM is 
differentiated from permanent neonatal diabetes mellitus (PNDM) 
by its remission in infancy or early childhood, with a possible relapse 
during adolescence
1). More than half of TNDM cases are associated 
with chromosomal anomalies of an imprinted locus at 6q24
2). Some 
cases of TNDM are caused by mutations in the KCNJ11 gene, which 
encodes the inwardly rectifying potassium-channel subunit (Kir6.2), 
and the ABCC8 gene, which encodes the sulfonylurea receptor 1 180      JH Kong, et al. • De Novo ABCC8 mutation in TNDM
Case report
A newborn male baby was referred from a primary clinic due to 
tachypnea and chest retraction after birth. The patient was born at 
35 weeks gestation by cesarean section delivery with a birth weight of 
2,300 g (25th–50th percentile). He was diagnosed with respiratory 
distress syndrome (RDS) and the RDS symptoms improved after 3 
days with ventilator care. Glucose monitoring revealed hyperglycemia 
with a glucose level of >300 mg/dL on the 7th day of life. There was 
no history of gestational diabetes. Physical examination did not reveal 
any dysmorphic features or instability. He was not receiving parenteral 
nutrition, and sepsis markers were negative. Hyperglycemia persisted 
without metabolic acidosis or ketonuria. The serum C-peptide was 
0.36 ng/mL (normal range, 1.0–3.5 ng/mL), and HbA1C was <1% 
(normal range, 2.1–7.7%). Autoantibodies associated with type 1 
diabetes were not present. He had no abnormal findings in diagnostic 
imaging and on function studies of other endocrine glands, such 
as the thyroid and adrenal glands. He was the second child of two 
siblings, and his parents and brother were clinically unaffected and 
had never experienced diabetic symptoms. 
The patient was started on subcutaneous neutral protamine 
hagedorn (NPH) and regular insulin, on which he was discharged 
to home following resolution of hyperglycemia. He remained NPH 
insulin-treated with a gradually increasing insulin requirement over 
the first year of life. At 14 months of age, the patient was prescribed 
glyburide (2.5 mg once daily) and was successfully transferred 
from insulin to sulfonylurea treatment with good glycemic control. 
HbA1C level dropped from 7.5% (mean: 7.3% on insulin) at 
start of sulfonylurea treatment to 5.9% at 12weeks after transfer. 
Hypoglycemia that developed several times during insulin therapy 
was not observed after the transfer onto sulfonylurea treatment. 
He entered remission at 16 months of age and we stopped his 
treatment. The patient currently exhibits normal growth and physical 
development and has not experienced any delays in achieving neuro-
developmental milestones.
The patient was initially screened for abnormalities in chromosome 
6q24. Since no 6q24 abnormality was identified, mutation screening 
was performed by sequence analysis of the entire coding region of 
the KCNJ11 and ABCC8 genes. Genomic DNA was extracted 
from the peripheral blood of the proband and family members (Fig. 
1A) by using a DNA extraction kit (SolGent, Daejeon, Korea). All 
participants provided written informed consent, and the study was 
conducted in compliance with the Institutional Review Board of 
Konyang University Hospital. 
Full exons of the KCNJ11 and ABCC8 genes were amplified 
to scan for mutations. Primers were designed from the introns 
surrounding the exons using Primer3 software (http://www.genome.
wi.mit.edu/cgi-bin/primer). Primer sequences are available upon 
request. Polymerase chain reaction (PCR) was performed in a total 
volume of 25 μ L containing 100 ng of genomic DNA, 10 pmol of 
each primer, and 2 × H-Taq Multiplex premix consisting of a PCR 
buffer, dNTP, MgCl2, and H-Taq DNA polymerase (SolGent) using 
a thermal cycler (GeneAmp PCR System 9700; Applied Biosystems, 
Foster City, CA, USA). The PCR conditions consisted of initial 
denaturation at 95℃ for 15 min, followed by 35 cycles at 95℃ for 
20 s, 60℃ for 20 s, 72℃ for 30 s, and a final extension at 72 ℃ for 
2 min. The PCR products were purified using a Millipore FB plate 
(Millipore, Billerica, MA, USA), and the nucleotide sequence was 
determined with an automatic genetic analyzer (ABI 3730XL) using 
the Big Dye Terminator Cycle Sequencing Ready Reaction Kit 
(Applied Biosystems, Foster City, CA, USA). The obtained sequences 
were then compared with the sequences from the control samples 
using SeqMan software (DNAStar, Madison, WI, USA), and the 
sequence variations were confirmed by analyzing both DNA strands. 
Fig. 1. Family pedigree and mutation analysis. (A) Pedigree of the TNDM 
patient shows the proband (black symbol) indicated by an arrow and 
the unaffected family members (open symbols). (B) Identification of a 
de novo missense mutation in the ABCC8 gene in the TNDM patient. 
Electropherograms show the sequence encompassing the heterozygous 
transition mutation (c.3547C>T) in ABCC8 exon 28 in the patient (right 
lower panel) and the corresponding wild-type sequences in the normal 
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Direct sequencing of ABCC8 exon 28 revealed a heterozygous 
C>T transition at nucleotide 3547 (Fig. 1B), leading to the 
substitution of a highly conserved, positively charged arginine with a 
neutral tryptophan at codon 1183 (Arg1183Trp). This mutation was 
absent in the patient’s parents (Fig. 1B). Parental identity was verified 
by genotyping 15 short tandem repeat markers using a PowerPlex 16 
system (Promega, Madison, WI, USA).  
Discussion
Neonatal diabetes mellitus, an uncommon cause of hyperglycemia 
during the period just after birth, presents within the first 6 months of 
life (with an estimated incidence of 1 in 400,000–500,000 neonates) 
and may persist for 2 weeks or more. TNDM is a clinically defined 
subgroup affecting ‒50% of children with neonatal diabetes
1, 2, 4). 
TNDM is differentiated from PNDM by its remission in infancy 
or early childhood. However, relapse in childhood or adolescence 
occurs in up to 50% of cases. Changes in insulin requirements and 
changes in the number of pancreatic beta cells have been implicated 
in the cause of the biphasic course, but the exact mechanism remains 
undetermined
1). Recently, TNDM has been shown to result from 
activating mutations in SUR1 that reduce the ability of ATP to close 
the KATP channel
5). Mutations in the ABCC8 gene are thought to 
account for about 10% of all cases of neonatal diabetes and frequently 
cause TNDM
6). 
In this study, we report the first case of a de novo mutation in the 
ABCC8 gene in a Korean patient with TNDM. This mutation is 
located in a region involved in linking the transmembrane domain 
to the nucleotide binding site in the SUR1 subunit of the pancreatic 
beta cell KATP channel
7). Among the identified mutations of the 
ABCC8 gene, the Arg1183Trp mutant is very rare. Two previous 
studies described patients with the same mutation but different 
clinical phenotypes that included diabetic ketoacidosis and 
neurological features, such as seizures and severe developmental 
delay. These patients experienced a complete remission within 2–13 
months
1, 7). Our patient has not experienced any ketoacidosis or 
ketonuria. Patients with TNDM are less likely to develop ketoacidosis 
than patients with PNDM, and some studies showed absence 
of ketoacidosis in TNDM patients with 6q24 abnormalities
2, 8). 
Lower incidence of diabetic ketoacidosis might be related to insulin 
resistance, which is associated with the onset of recurrence in the 
TNDM patients
1, 9). At 21 months of age, our patient currently 
exhibits normal growth and physical development without seizures 
or delays in achieving neuro-developmental milestones, although he 
experienced a later remission than did previous cases. 
Our patient had been receiving NPH insulin injections for 
glycemic control before the mutation analysis revealed his SUR1 
mutation. Based on the analysis result, treatment with glyburide (a 
sulfonylurea) was initiated. Previous reports have indicated that oral 
sulfonylurea therapy in patients with mutations of the KATP channel 
genes, ABCC8 and KCNJ11, can result in glycemic control that 
is as good, or better, than that achieved with subcutaneous insulin 
injection
6, 10-13). Our patient discontinued insulin (after 13 months 
of therapy) after a successful response to glyburide (2.5 mg per day). 
After entering remission at 16 months old, he is currently maintaining 
euglycemia without any insulin or oral hypoglycemic drugs. 
In conclusion, we report the first de novo Arg1183Trp mutation in 
the ABCC8 gene in a Korean TNDM patient with a normal neuro-
developmental phenotype. Our findings have implications for the 
diagnosis, clinical management, and genetic counseling of a child 
who exhibits the phenotypic features of TNDM without a familial 
history of diabetes. We recommend that all patients with non-6q24 
TNDM be tested for mutations in the ABCC8 and KCNJ11 genes 
in order to establish appropriate glycemic control by changing to oral 
sulfonylurea therapy. 
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